Why GW Pharmaceuticals (GWPH) Stock Is Soaring Today

NEW YORK (TheStreet) -- GW Pharmaceuticals (GWPH) stock is soaring, up 31.1% to $60.37 in trading on Tuesday.

The increase follows coverage initiation on the cannabis prescription drug company's stock with an "overweight" rating by analysts at Morgan Stanley (MS). The firm set a $103 price target on the company's shares.

Must Read: Warren Buffett's 10 Favorite Stocks

SELL NOW: If you own any of the 900 stocks that TheStreet Quant Ratings has identified as a 'Sell'...you could potentially lose EVERYTHING in the next 6-12 months.
 Learn more.

Analysts see the company's cannabis based epilepsy treatment drug, Epidiolex, as having "strong potential, with the epilepsy program driving valuation."

"While small and still anecdotal, there is a consistently strong and building set of data (case cohort and controlled) which highlight the positive impact of Cannabidiol  on refractory epilepsy pts," the firm said.

GWPH Chart

GWPH data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Snap, Kinder Morgan, Iconix Brands: 'Mad Money' Lightning Round

Stay Focused on the Green Lights: Cramer's 'Mad Money' Recap (Wed 8/30/17)

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Snap-On, Teekay Shipping, FLIR Systems, GW Pharmaceuticals: 'Mad Money' Lightning Round

Time to Raise Some Cash: Cramer's 'Mad Money' Recap (Tuesday 8/1/17)